ProNova expands European footprint with Dutch deal
CONTACT: Bill Hansen | (865) 360-1015 | email@example.com
Maryville, TN — ProNova Solutions has been selected as equipment vendor for a new proton therapy center in Amsterdam, slated to begin treating patients in 2018.
The Amsterdam Proton Therapy Center (APTC)—a partnership of the Academic Medical Center, the VU University Medical Center and the Netherlands Cancer Institute—announced ProNova has been selected to provide treatment systems for the new facility, which will have the capacity to treat about 600 patients per year with proton therapy.
ProNova Solutions was founded in 2012 for the purpose of developing a lower-cost, more technologically advanced proton therapy treatment system. Leveraging its founders’ past experience in the development and global commercialization of PET and PET/CT technology, ProNova utilizes proprietary, superconducting technology to build compact proton therapy gantries at less cost that competing systems, improving access to proton therapy for patients who need it. ProNova has also signed agreements with proton therapy centers under development in China and the United Kingdom.
“The partnership with APTC further bolsters our leadership in proton therapy equipment innovation and further establishes our presence in the European market,” said Joe Matteo, ProNova Solutions co-founder and division president. “We are excited to be part of this unique collaboration, which will make proton therapy available to cancer patients in the Netherlands and abroad and contribute to clinical research in this important field.”
APTC will take advantage of ProNova’s SC360 system’s ability to create “cone beam” CT images in order to more precisely target tumor sites and customize treatment plans. The systems also feature 360-degree rotation capability, pencil beam scanning delivery allowing for intensity modulated proton therapy and optional PET Imaging
About ProNova Solutions, LLC
ProNova is committed to making proton therapy accessible to a greater number of patients and physicians worldwide. Founded by the leaders of CTI Molecular Imaging, ProNova’s team brought positron emission tomography (PET) technology out of the laboratory and made it a clinical reality for millions of cancer patients. Our team’s early work revolutionized cancer diagnostics and helped to develop an industry with over 350 cyclotrons, more than 3,000 PET & PET/CT systems and 160 PET radiopharmaceutical distribution centers installed around the world today. The same team is redefining cancer treatment once again with the introduction of the SC360 proton therapy system.